Two AstraZeneca therapies accepted in Scotland
Tezspire is a drug for severe asthma and Forxiga is used to treat chronic heart failure
Read Moreby John Pinching | Aug 8, 2023 | News | 0
Tezspire is a drug for severe asthma and Forxiga is used to treat chronic heart failure
Read Moreby John Pinching | Jul 21, 2023 | News | 0
The inhaler supports appropriate individuals presenting with asthma and chronic obstructive pulmonary disease
Read Moreby John Pinching | Sep 21, 2022 | News | 0
Tezspire is a maintenance therapy for patients with no phenotype or biomarker limitations
Read Moreby John Pinching | Jul 12, 2022 | News | 0
The partnership will deliver digital therapy support for asthma and COPD patients
Read Moreby John Pinching | May 16, 2022 | News | 0
PT027 is being developed through a partnership involving AstraZeneca and Avillion
Read Moreby Lucy Parsons | Sep 9, 2021 | News | 0
Positive results revealed from two Phase III trials of potential asthma therapy
Read Moreby Lucy Parsons | Sep 6, 2021 | News | 0
TSLP blocker reduced exacerbations in patients with severe asthma and comorbid nasal polyps
Read Moreby Lucy Parsons | Jul 8, 2021 | News | 0
Priority review comes following positive results from the Phase III NAVIGATOR trial
Read Moreby Lucy Parsons | May 18, 2021 | News | 0
Detailed results found Dupixent improved overall asthma control in children aged six to 11 years old
Read Moreby Lucy Parsons | Mar 18, 2021 | News | 0
GSK’294 is designed to deliver long-acting suppression of IL-5 in severe eosinophilic asthma patients
Read Moreby Lucy Parsons | Mar 5, 2021 | News | 0
Sanofi is also planning an EU regulatory submission for Dupixent in the same indication
Read Moreby Lucy Parsons | Feb 17, 2021 | News | 0
New data shows overuse of SABA relievers is responsible for 250,000 tonnes of CO2 emissions annually
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479